Investing Profile

Bali Muralidhar

InvestorVC

Managing Partner at Abingworth

Photo of Bali Muralidhar, Managing Partner at Abingworth

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Abingworth Managing Partner
$15.0M - $30.0M
$22.5M
9
$465M
CompanyStageDateRound SizeTotal Raised
Anjarium Biosciences
Series ASep 2021C56M
CHF56M
CymaBay Therapeutics
Post-IPO DebtAug 2021$100M
$140M
Co-investors: Andrew Schwab (5am Ventures), Tony Evnin (Venrock)
Wugen
Series BJul 2021$170M
$170M
Co-investors: John McKearn (RiverVest)
Glycomine
Series BJun 2021$35M
$35M
Co-investors: Jim Trenkle (Sanofi Ventures), Niall O’Donnell (RiverVest)
Reneo Pharmaceuticals
Series BDec 2020$95M
$150M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Niall O’Donnell (RiverVest)
NuCana BioMed
Post-IPO EquityOct 2020$80M
$140M
Co-investors: James Healy (Sofinnova Investments)
Spruce Biosciences
Series BFeb 2020$88M
$88M
Onbone
Venture RoundApr 2015€10M
€10M